@my_ueg @EASLnews Aleksander Krag opening the WHO-European Alcohol Health Alliance Symposium at UN City in Copenhagen right now: 25 EU health organizations getting together to work on advocacy to reduce alcohol-related harm in Europe!

@my_ueg @OEGGH_AUT UEG-ÖGGH Round table on CRC-Prevention & Screening happening now at @UegWeek in Vienna with the goal of implementing an universal, nationwide, quality-controlled CRC screening program in Austria: we can reduce the incidence of CRC here!

@myUEG @OEGGH_AUT Live from #AASLD President #Norah_Terrault on New US National HCV Elimination Plan. Key element: primary patient care, with Hepatologist support. Why the hell is #Austrian_Hauptverband still not allowing all hepatologist to treat #HCV but only few centers???

RT @my_ueg: As of today, the White Book 2 is now published in @uegjournal! 👏 The report identifies that digestive diseases affect over 300…

@my_ueg @EASLnews Today we kick off the Austrian annual GI- & Hepatology Meeting with the PG-course in Emergencies in GI- & Liver Diseases. Presentations by young clinicians and expert discussions by the likes of #Thoma_Reiberger, #Michael_Trauner, and #Peter_Fickert

RT @AleksanderKrag: Great discussion on how to ➡️ increase value of being a @my_ueg member society ⬆️ ➡️ increase member base among member…

Attending #DRILLS (nomen est omen) this weekend in Delhi, India: over 1000 yound Indian hepatologist being trained through a purely case-based program. Really thrilled by the level of expertise and the cases, some of which would never make it into differential diagnosis in EU!

@EASLnews @my_ueg Simona Bota from Klinikum Klagenfurt presenting our data on the severe impact of cirrhotic cardiomyopathy on Acute Kidney Injury (AKI): excellent prospective data from a community hospital!

@rabataller Dear Ramon, thank you! Very important issue to remember. Depending on geopraphy, these figures likely can be even higher!

RT @joostphdrenth: @MarkusPeck1 on liver transplant for #HCC after local cure ✅ difficult topic ✅ key is prediction of therapy success @EAS…

@rabataller Completely agree, Ramon. This seems to be the biggest problem to avoid if we would be seriously considering to rename NAFLD: significant alcohol- consumption, the most important cause of chronic liver disease in Europe, has to be ruled out in metabolic liver disease.

@rabataller @MassimoPinzani Could not agree more, Ramon! 👍🏻

@my_ueg @EASLnews @IasLiver UEG-public Affairs is proud to support EMA through the years through its network of healthcare professionals‘ organisations. This part of our work is hardly visible but very important for the future of Medicine in the EU.

RT @joostphdrenth: Getting in shape to bring the @UEGJournal to new heights ✅ while this 🚴 does not move the Journal will ✅ looking forward…

If you are looking for something more than Hepatology: skiing Gerlitzen, just 20 min from #Kinikum_Klagenfurt! Back in the afternoon to write an editorial for @Gut_BMJ on an interesting piece on #MAFLD HCC from the #ITALICA-group.

@my_ueg @EASLnews Congratulations, Matthias & Bernhard! We are all desperate for predictive biomarkers for IO-therapy for Liver Cancer. Fantastic simple, easy-to-use score to help with patient selection between IO- and TKI-based therapies. Check it out at

RT @joostphdrenth: COVID‐19 and #digestivehealth ✅ Implications for prevention, care and the use of #COVID19 vaccines in vulnerable patient…

RT @BavenoVII: 📍Second day of the pre-#BavenoVII premeeting Yesterday intense discussions were focused on 🪙 HVPG as a gold standard 🔎 Non-…

Interesting news, indeed. If you read it in a pragmatic way though: IO-mono seems to be unable to beat sorafenib and we will not know how it compares to the current SOC. Looking forward to the final data and the AE-profile.